Loading clinical trials...
Loading clinical trials...
A Phase Ib, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance , Pharmacokinetics and Effectiveness of TQ-A3334 Tablets in Patients With Advanced Non-small Cell Lung Cancer
Conditions
Interventions
TQ-A3334
Anlotinib
Locations
1
China
Jinling Hospital
Nanjing, Jiangsu, China
Start Date
July 6, 2020
Primary Completion Date
January 31, 2021
Completion Date
January 31, 2021
Last Updated
July 8, 2020
NCT07190248
NCT06305754
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions